Media Articles Related to Zovirax Topical (Acyclovir Topical)
Cold Sores (Nongenital Herpes Simplex Infections)
Source: MedicineNet Canker Sores Specialty [2013.12.09]
Title: Cold Sores (Nongenital Herpes Simplex Infections)
Category: Diseases and Conditions
Created: 6/16/1999 7:38:00 PM
Last Editorial Review: 12/9/2013 12:00:00 AM
Published Studies Related to Zovirax Topical (Acyclovir Topical)
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
BACKGROUND: Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity. The immune response is also responsible for important clinical manifestations, including oedema and pain. The dual role of immune responses (protection, pathology) is well recognized in other infectious diseases. The addition of corticosteroids to antimicrobial agents has been associated with improvement in some of these diseases. OBJECTIVE: We evaluated the combination of oral valacyclovir plus topical clobetasol compared to placebo for recurrent HSL... CONCLUSIONS: This pilot study supports the addition of topical corticosteroids to an oral antiviral agent for the treatment of HSL. Larger studies need to confirm the safety and efficacy of this approach.
Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. 
OBJECTIVE: To compare silica gel with acyclovir cream in the treatment of recurrent herpes labialis... CONCLUSIONS: Silica gel was as effective in the treatment of recurrent herpes labialis as acyclovir and equally well tolerated and tended to take effect more quickly. Therefore, silica gel could prove a useful alternative to topical acyclovir.
A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. [2007.01]
OBJECTIVE: The objective of this study was to assess the efficiency of topical applications of podophyllin resin (25%) (P) versus podophyllin resin (25%) together with acyclovir cream (5%) (PA) in the treatment of oral hairy leukoplakia (OHL) in accordance with the following criteria: (1) number of applications necessary for the total clinical resolution of OHL; (2) correlation between the decrease of lesion size and the number of applications; (3) total clinical resolution of OHL; and (4) clinical reevaluation 12 months after the end of treatment... CONCLUSIONS: The present study demonstrated the following: (1) P and PA topical treatments presented a similar average number of applications performed weekly; (2) both groups showed the same clinical response at 12 months post-therapy; and (3) PA presented a 100% clinical resolution and a continuous decrease in OHL size over the course of weekly applications.
Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. [2006.08.15]
BACKGROUND: Multiple studies of the use of acyclovir for the treatment of herpes labialis have suggested that the nominal efficacy of the topical formulation is the result of inadequate penetration of the drug into the target site of infection, the basal epidermis... CONCLUSIONS: Single-dose topical iontophoresis of acyclovir appears to be a convenient and effective treatment for cold sores and merits further clinical investigation.
Role of acyclovir gel in herpes simplex: clinical implications. [2003.07]
CONCLUSIONS: The results demonstrate that a five-fold reduction in the ACY content in liposomal gel is sufficient for the complete healing of herpetic lesions in HSV-1 and HSV-2 infection. The increased duration of topical therapy may be acceptable for patients suffering from mild herpetic lesions because of the advantage of avoiding systemic and local side effects
Clinical Trials Related to Zovirax Topical (Acyclovir Topical)
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) [Recruiting]
Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in babies.
Appropriate dosing of acyclovir is known for adults and children but acyclovir has not been
adequately studied in full-term or premature neonates. HSV is a very serious infection in
babies <6 months of age and often results in death or profound mental retardation. HSV
leads to profound mental retardation in young infants because the virus attacks the central
The investigators hypothesize that the currently recommended dose of acyclovir is inadequate
to produce adequate blood levels to combat herpes simplex infection. The investigators
propose to study acyclovir levels in the blood of babies who are placed on acyclovir to
treat a suspected HSV infection. This will allow them to determine the appropriate dose in
premature infants. This is an unmet public health need because it is likely that the drug
behaves differently in premature infants than it does in term infants and older children.
Premature babies have more body water and less body tissue. Their kidneys are more immature
and do not function as well as full term infants. Premature neonates are also at the
greatest risk from herpes infection because they have poorly functioning immature immune
systems. Early and appropriate treatment with acyclovir has resulted in improved outcome in
Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS) [Completed]
To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303
gel in combination with acyclovir, relative to acyclovir alone, for the treatment of
recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and
neighboring areas, in patients with AIDS.
Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease [Recruiting]
Meniere's disease is a chronic illness that affects a substantial number of patients every
year worldwide. The disease is characterized by intermittent episodes of vertigo lasting
from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural
pressure. It has recently been suggested that viral etiologies specially Herpes virus might
be the underlying reason. The investigators study is a randomized, double- blinded
placebo-controlled clinical trial in Amiralam Hospital. In this study the primary objective
is to assess efficacy of Acyclovir in control of symptoms in patients with Meniere's disease
specially their vertigo attacks. Inclusion criteria would be patient's willingness to
participate in the study and follow ups, being 18 years old or older, having at least 2
vertigos per month each at least 20 min, interfering with function, and not on medication
for Meniere's disease for at least 3 months before the trial. They should not have any
history of allergy to Acyclovir, renal insufficiency or Creatinine above 1. 5 mg/dl, hepatic
enzymes more than three times normal, serious uncontrolled illness, be pregnant or nursing
or have previous surgeries on Endolymphatic Sac. Participants will be randomly placed in 2
different arms getting either Acyclovir 400 mg or placebo (inert ingredient). They will take
the medication for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a
day for the last 10 days. Patients will report changes in their symptoms 10 days after
initiating the drug and in 1, 3, 6 month intervals.
Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2) [Recruiting]
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV
viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are
starting HIV treatment for the first time.
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]